On April 17th 2013, some top notch companies are in line to issue their first quarter 2013 earnings. The previews of these companies by the analysts are as follows:
Bank of America Corp (NYSE:BAC): Analysts are forecasting a decline in profit for Bank of America in its first quarter 2013 results. The Bank posted earnings of 31 cents per share in the first quarter of 2012, but the analysts have lowered their estimates to 23 cents earnings per share for the latest quarter.
JPMorgan’s Erdoes From Delivering Alpha: How The Pandemic Is Triggering Deglobalization
The more connected the world has become, the easier it has become for investors to look outside their home country to find alpha. However, the pandemic has resulted in a shift toward deglobalization. In an interview on CNBC's Delivering Alpha, JPMorgan Asset and Wealth Management CEO Mary Callahan Erdoes, Alibaba Executive Vice Chairman Joseph Tsai Read More
Three months back, the consensus estimate was at 21 cents per share, but the company manages to improve itself from that level up to 23 cents per share. Analysts have forecasted earnings coming in at $1.01 per share for the full fiscal year. Revenue as per the analysts will decline 12.7 percent year over year to $23.5 billion for the first quarter. The company is estimated to post revenue of $90.99 billion for the full fiscal 2013.
Bank of America Corp (NYSE:BAC) posted lower revenues in the previous two quarters. For the last quarter of 2012, revenue came in at $22.31 billion, 24.8 percent less than the corresponding period of the previous year. In the third quarter of 2012, revenue declined 27.8 percent.
Abbott Laboratories (NYSE:ABT): For the first quarter of fiscal 2013, analysts are expecting earnings to come in at $0.41 per share. The revenue for the company, according to the analysts will be posted at $5.42 billion.
Analysts are holding negative ratings for the company in the latest quarter. The average estimate from the past three months swung from $0.49 to $0.45. For full fiscal 2013, analysts are expecting profit to come in at $2.01, which is higher than the previous estimates made three months back.
In the past four quarters, Abbott Laboratories (NYSE:ABT) has outperformed the analysts’ expectations every time. There can be upside in stock trading if the company succeeds in doing so again.
Textron Inc. (NYSE:TXT): Analysts are positive regarding the first quarter 2013 earnings of Textron. Analysts are expecting a profit of 47 cents, which will be an increase from 41 cents from the corresponding quarter of 2013.
The earnings for the full year 2013 are expected to come in at $2.27 per share. Revenue, according to analysts, will be somewhere around $2.89 billion for the latest quarter, which will be an increase of 1.2 percent compared to the previous year’s $2.86 billion. The revenue for the full year is expected to be $12.84 billion. Around 70 percent of analysts believe that Textron Inc. (NYSE:TXT) is a buy.
Bank of New York Mellon Corporation (NYSE:BK): Analysts are expecting a poor performance by the company in the first quarter of 2013. The general consensus estimate has come in at 52 cents per share, a decline from 53 cents per share from the previous year. For a full year, the estimate is $2.30 per share.
Revenues are expected to decline by 5.4 percent year over year to $3.59 billion for the quarter, a decline from $3.79 in the previous year. Revenue for 2013 is expected at $14.71 billion.
In the fourth quarter of 2012, revenue surged 1.4 percent, after declining 1.1 percent in the third quarter of 2012. Analysts are recommending a hold position in the stock.
Dover Corp (NYSE:DOV): The company is set to announce its earnings on April 17th with earnings expectations that have declined from $1.12 per share to $1.08 per share. As per analysts, earnings are expected to increase 2.9 percent from the first quarter 2012 to $1.05 per share.
According to analysts the company will post earnings of $5.25 per share for full fiscal 2013.
Revenue is expected to come in at $2.08 billion for the first quarter, an increase of 0.8 percent over the previous year’s $2.06 billion. Revenue is expected to be at $9.73 billion for the full year. Around 75% of analysts have maintained their buy rating for the stock.